Antibody-induced secondary failure of botulinum neurotoxin therapy is correlated to dose

Takeaway

  • This study supports the use of the lowest possible dose of botulinum neurotoxin (BoNT) therapy for muscular hyperactivity as well as avoiding unnecessary switching of formulations.

Why this matters ?

    Clinical relevance of neutralizing antibodies (NABs) in unselected patient populations is currently unclear.